Patent details

Basic Information

Publication number:

EP2644204

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP131583916

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab

French Title of Invention:

Combinaisons de conjugué de médicament-anticorps anti-HER2 et du pertuzumab

German Title of Invention:

Kombination aus einem Anti-HER2-Antikörperwirkstoffkonjugat und Pertuzumab

SPC Number:

Dates

Filing date:

10/03/2009

Grant date:

19/04/2017

EP Publication Date:

02/10/2013

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

19/04/2017

EP B1 Publication Date:

19/04/2017

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

10/03/2018

Expiration date:

10/03/2029

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

19/04/2017

 

 

Name:

Genentech, Inc.

Address:

1 DNA Way, South San Francisco, CA 94080, United States (US)

Inventor

1

Name:

Berry, Leanne

Address:

United States (US)

2

Name:

Phillips, Gail, Lewis

Address:

United States (US)

3

Name:

Sliwkowski Mark, X.

Address:

United States (US)

Priority

Priority Number:

37410 P

Priority Date:

18/03/2008

Priority Country:

United States (US)

Classification

IPC classification:

A61K 39/395; A61K 45/06; A61P 35/00; A61K 47/50;

Publication

European Patent Bulletin

Issue number:

201716

Publication date:

19/04/2017

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages
31/07/2018	Outgoing Correspondence	1